Everolimus Plus CHOP May Be Effective for Peripheral T-cell Lymphoma

Share this content:
Everolimus in combination with CHOP was effective as first-line treatment for patients with peripheral T-cell lymphoma.
Everolimus in combination with CHOP was effective as first-line treatment for patients with peripheral T-cell lymphoma.

Everolimus in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) was effective as first-line treatment for patients with peripheral T-cell lymphoma (PTCL), a study published in the Journal of Clinical Oncology has shown.1

Because everolimus, an oral mammalian target of rapamycin  inhibitor, has demonstrated single-agent activity against relapsed lymphoma, researchers sought to evaluate everolimus plus CHOP for the frontline treatment of patients with PTCL. For the phase 2 study, researchers enrolled 30 patients and assigned them to receive everolimus 5 mg daily on days 1 to 14 in 3-week cycles for a total of 6 cycles plus CHOP chemotherapy.

Researchers used immunohistochemistry to assess the expression of phosphatase and tensin homology (PTEN) and phosphorylated S6 kinase (pS6K) as a response, in addition to determining the overall response rate.

Results showed that the objective response rate was 90% with 17 complete responses and 10 partial responses. When subgroup analyses were performed, researchers found that the 3 patients with angioimmunoblastic T-cell lymphoma (AITL) had a 100% complete response rate, while patients with PTCL-not-otherwise specified and ALK-negative anaplastic large-cell lymphoma (ALCL) had a 63% and 29% complete response rate, respectively.

The study also demonstrated that PTEN expression was preserved in all patients with AITL but only in 67% of patients with ALCL, suggesting that the efficacy of the regimen may be association with the preservation of PTEN.

RELATED: Chidamide Shows Activity in Peripheral T-cell Lymphoma

In terms of safety, most common toxicities were hematologic adverse events. A total of 80% of patients experienced at least 1 event of grade 3 or 4 neutropenia, and 60% of patients experienced grade 3 or 4 thrombocytopenia.

Reference

  1. Kim SJ, Shin D-Y, Kim JS, et al. A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas [published online ahead of print February 8, 2016]. Ann Oncol. doi: 10.1093/annonc/mdv624.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters